Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 2/20 | 0.32 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.32 |
| ▸ | CA1 | P00915 | 2/20 | 0.31 |
| ▸ | CA2 | P00918 | 2/20 | 0.31 |
| ▸ | CA9 | Q16790 | 2/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA3 | P07451 | 1/20 | 0.31 |
| ▸ | CA4 | P22748 | 1/20 | 0.31 |
| ▸ | CA6 | P23280 | 1/20 | 0.31 |
| ▸ | CA5A | P35218 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15307251 | 0.85 | LPL (0.39) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL3124777 | 0.79 | CA1 (0.48) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL25815214 | 0.74 | LIPG (0.44) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL18483348 | 0.71 | NOS2 (0.45) | — | |
| SCHEMBL24568839 | 0.71 | KDR (0.40) | — | |
| SCHEMBL29694450 | 0.71 | KDR (0.40) | — | |
| SCHEMBL13006325 | 0.70 | CA1 (0.46) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL31262570 | 0.69 | CYP2C19 (0.47) | LPLLIPG | |
| SCHEMBL16555162 | 0.68 | LPL (0.39) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL28599147 | 0.66 | LPL (0.38) | LPLLIPGCA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3915988-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | BioSplice Therapeutics, Inc. (US) | 2021-12-01 | — | — | EP | disclosed |